KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Population Pharmacokinetics and Exposure-Response Analysis of First-Line Osimertinib Plus Chemotherapy in Patients with EGFR-Mutated Advanced NSCLC.

Jincheng Yang, Damilola Olabode, Aarti Sawant-Basak, Richard Baldry, Karthick Vishwanathan, Srinivas Bachina, Alexandar Todd, Dana Ghiorghiu, Yuri Rukazenkov, Diansong Zhou, Azar Shahraz

Clin Pharmacol Ther 118(5) 1110-1121

PMID40637621
PMCIDPMC12598126
DOI10.1002/cpt.3759
发表日期2025-07-10
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:非 KM 图;Figure 3:森林图/亚组分析图;Figure 4:森林图/亚组分析图;Figure 5:非 KM 图。
摘要

摘要

Osimertinib, a third-generation, central nervous system-active epidermal growth factor receptor-tyrosine kinase inhibitor, potently and selectively inhibits epidermal growth factor receptor-tyrosine kinase inhibitor sensitizing and T790M resistance mutations, with efficacy in epidermal growth factor receptor-mutated non-small cell lung cancer. In FLAURA2 (NCT04035486), first-line osimertinib plus platinum-pemetrexed chemotherapy showed significant improvement in progression-free survival over osimertinib monotherapy in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer. A population pharmacokinetics analysis using cumulative pharmacokinetics data from 2,196 patients across six studies (AURA, AURA2, AURA3, ADAURA, FLAURA, and FLAURA2) assessed pharmacokinetics and its variability due to intrinsic and extrinsic factors. Upon a formal covariate search, none of the covariates retained in the final model had a clinically meaningful impact on the pharmacokinetics of osimertinib and its active metabolite, AZ5104. The osimertinib exposure derived from the population pharmacokinetics model was used to evaluate the relationship between osimertinib exposure and progression-free survival, as the efficacy primary end point, in the FLAURA2 combination arm. A Cox proportional hazard analysis indicated no exposure-progression-free survival relationship for osimertinib and its metabolite; the number of pemetrexed cycles was likely to be associated with progression-free survival. No exposure-safety relationship was observed between osimertinib exposure and the occurrence of adverse events, including those leading to osimertinib dose interruption/reduction/discontinuation, and other pre-determined adverse events. These results further reinforce the benefits of the FLAURA2 clinical data that establish osimertinib 80 mg once daily plus chemotherapy as a first-line treatment for patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Parent‐metabolite model. CL ptot , total clearance of the parent compound; CL m , total clearance of the metabolite; FM, fraction metabolized; KA, first‐order absorption; V m , volume of distribution of the metabolite.
非 KM Figure
Figure 2( a ) Osimertinib and ( b ) AZ5104 plasma concentrations across the six studies included in the PopPK analysis (AURA, AURA2, AURA3, FLAURA, ADAURA and FLAURA2). Open circles represent osimertinib and AZ5104 plasma concentrations since the first dose, in weeks. PopPK, population pharmacokinetics.
非 KM Figure
Figure 3Forest plot depicting the impact of covariates retained in the final PopPK model on ( a ) osimertinib AUC ss , ( b ) AZ5104 AUC ss , ( c ) osimertinib Cmax ss , and ( d ) AZ5104 Cmax ss . The reference (typical patient) is simulated based on White patients with a median baseline body weight of 62 kg and a median baseline albumin level of 40 g/L. Black diamonds represent the ratio of exposure parameters for the 5th and 95th percentile of the relevant covariate relative to the median exposure estimates for continuous covariates and relative to the most frequent category for categorical covariates. Maroon and gray shaded areas represent bioequivalence 0.8–1.25 and 0.5–2.0 reference ranges, respectively. AUC ss , area under the plasma concentration‐time curve over a dosing interval at steady state; Cmax ss , maximum plasma concentration at steady state; PopPK, population pharmacokinetics.
非 KM Figure
Figure 4Kaplan–Meier curves of PFS in the FLAURA2 osimertinib plus chemotherapy arm stratified by ( a ) osimertinib AUC ss and ( b ) number of pemetrexed cycles. ( c ) Forest plot of the final Cox proportional model depicting the impact of pemetrexed cycles on PFS. AUC ss , area under the plasma concentration‐time curve over a dosing interval at steady state; CI, confidence interval; HR, hazard ratio; PFS, progression‐free survival.
非 KM Figure
Figure 5Logistic regression analyses between osimertinib AUC ss and the occurrence of pre‐selected AEs in the FLAURA2 osimertinib plus chemotherapy arm. Boxplots show the probability of each AE type by quartile of osimertinib AUC ss . AE, adverse event; AUC ss , area under the plasma concentration‐time curve over a dosing interval at steady state; ILD, interstitial lung disease; LVEF, left ventricular ejection fraction.
非 KM Figure